Taff Jones

Summary

Affiliation: ID Biomedical Corp
Country: Canada

Publications

  1. ncbi request reprint A chimeric live attenuated vaccine against Japanese encephalitis
    Taff Jones
    ID Biomedical Corp of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada
    Expert Rev Vaccines 3:243-8. 2004
  2. ncbi request reprint Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology
    Sonya L Cyr
    McGill Center for Tropical Diseases, Montreal General Hospital, Montreal, Quebec H3G IA4, Canada
    Vaccine 25:5378-89. 2007
  3. ncbi request reprint Remune. Immune Response
    Derhsing Lai
    Vincogen Corp, Yardley, PA 19067, USA
    Curr Opin Investig Drugs 3:391-8. 2002
  4. ncbi request reprint Resiquimod 3M
    Taff Jones
    ID Biomedical Corp of Quebec, 7150 Frederick Banting, Suite 200, Ville St Laurent, Quebec H4S 2A1, Canada
    Curr Opin Investig Drugs 4:214-8. 2003
  5. ncbi request reprint A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity
    Taff Jones
    ID Biomedical Corporation of Quebec, 7150 Frederick Banting, Suite 200, Ville Saint Laurent, Montreal, Que, Canada H4S 2A1
    Vaccine 21:3706-12. 2003
  6. ncbi request reprint Technology evaluation: ChimeriVax-DEN, Acambis/Aventis
    Taff Jones
    ID Biomedical Corp, 7150 Frederick Banting, Montreal, H4S 2A1, Quebec, Canada
    Curr Opin Mol Ther 6:443-50. 2004
  7. ncbi request reprint Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection
    Taff Jones
    ID Biomedical Corporation of Quebec, 525 Cartier Blvd West, Laval, Montreal, Que, Canada H7V 3S8
    Vaccine 24:1625-32. 2006
  8. ncbi request reprint Boostrix (GlaxoSmithKline)
    Taff Jones
    ID Biomedical Corp of Quebec, Canada
    IDrugs 8:656-61. 2005
  9. ncbi request reprint Peru-1 5 (AVANT)
    Taff Jones
    ID Biomedical Corp of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada
    Curr Opin Investig Drugs 5:887-91. 2004
  10. ncbi request reprint ChimeriVax-JE. Acambis
    Taff Jones
    ID Biomedical Corp, 7150 Frederick Banting, Ville St Laurent, Quebec H4S 2A1, Canada
    Curr Opin Investig Drugs 4:1019-22. 2003

Detail Information

Publications21

  1. ncbi request reprint A chimeric live attenuated vaccine against Japanese encephalitis
    Taff Jones
    ID Biomedical Corp of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada
    Expert Rev Vaccines 3:243-8. 2004
    ..It therefore appears to be a cost-effective prophylactic vaccine against this debilitating disease...
  2. ncbi request reprint Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology
    Sonya L Cyr
    McGill Center for Tropical Diseases, Montreal General Hospital, Montreal, Quebec H3G IA4, Canada
    Vaccine 25:5378-89. 2007
    ..Proteosome-based eRSV vaccines can therefore protect against RSV challenge in mice without increasing the risk of pulmonary immunopathologic responses...
  3. ncbi request reprint Remune. Immune Response
    Derhsing Lai
    Vincogen Corp, Yardley, PA 19067, USA
    Curr Opin Investig Drugs 3:391-8. 2002
    ..Analysts at Lehman Brothers predicted in September 2001, that the product would be launched onto the market with sales of US$150 million in 2004...
  4. ncbi request reprint Resiquimod 3M
    Taff Jones
    ID Biomedical Corp of Quebec, 7150 Frederick Banting, Suite 200, Ville St Laurent, Quebec H4S 2A1, Canada
    Curr Opin Investig Drugs 4:214-8. 2003
    ..The compound has also been investigated for the potential treatment of various other diseases, including other viral infections and eczema and as a vaccine adjuvant...
  5. ncbi request reprint A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity
    Taff Jones
    ID Biomedical Corporation of Quebec, 7150 Frederick Banting, Suite 200, Ville Saint Laurent, Montreal, Que, Canada H4S 2A1
    Vaccine 21:3706-12. 2003
    ..n. Proteosome-rHA vaccine induced more complete protective immunity than the same doses of unformulated rHA given i.n. or i.m...
  6. ncbi request reprint Technology evaluation: ChimeriVax-DEN, Acambis/Aventis
    Taff Jones
    ID Biomedical Corp, 7150 Frederick Banting, Montreal, H4S 2A1, Quebec, Canada
    Curr Opin Mol Ther 6:443-50. 2004
    ..Acambis, in collaboration with Aventis Pasteur, is developing a chimeric vaccine based on a recombinant yellow fever vaccine for the potential prevention of dengue virus infection. The vaccine is undergoing phase I clinical trials...
  7. ncbi request reprint Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection
    Taff Jones
    ID Biomedical Corporation of Quebec, 525 Cartier Blvd West, Laval, Montreal, Que, Canada H7V 3S8
    Vaccine 24:1625-32. 2006
    ..Mice immunized intranasally with Protollin-F1-V were 100% protected against aerosol challenge with 170 LD50 of Y. pestis and 80% against 255 LD50...
  8. ncbi request reprint Boostrix (GlaxoSmithKline)
    Taff Jones
    ID Biomedical Corp of Quebec, Canada
    IDrugs 8:656-61. 2005
    ..GlaxoSmithKline plc has developed and launched Boostrix, a subunit vaccine for use in adolescents and adults as a booster immunization against diphtheria, tetanus and pertussis (DTPa) infections...
  9. ncbi request reprint Peru-1 5 (AVANT)
    Taff Jones
    ID Biomedical Corp of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada
    Curr Opin Investig Drugs 5:887-91. 2004
    ..A phase II trial of Peru-15 was ongoing in June 2003, and as of September 2003 AVANT was planning a phase III trial in a developing country, and phase IIb and phase III challenge studies in travelers...
  10. ncbi request reprint ChimeriVax-JE. Acambis
    Taff Jones
    ID Biomedical Corp, 7150 Frederick Banting, Ville St Laurent, Quebec H4S 2A1, Canada
    Curr Opin Investig Drugs 4:1019-22. 2003
    ..By May 2003, Acambis had initiated a phase II trial in Australia...
  11. ncbi request reprint Protollin: a novel adjuvant for intranasal vaccines
    Taff Jones
    ID Biomedical Corporation of Quebec, 7150 Frederick Banting, Ville St Laurent, Montreal, QC, Canada H4S 2A1
    Vaccine 22:3691-7. 2004
    ..Mice immunized with Protollin-rHA were completely protected against lethal challenge with influenza virus, demonstrating that Protollin is an effective mucosal adjuvant for prophylactic vaccines...
  12. ncbi request reprint C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine
    Sonya L Cyr
    McGill Center for Tropical Diseases, Montreal General Hospital, Montreal, Quebec, Canada H3G IA4
    Vaccine 25:3228-32. 2007
    ..This new model will permit us to dissect the respective roles of the TLR2 and TLR4 ligands contained in the vaccine using TLR knock-out animals established on the C57Bl/6 background...
  13. ncbi request reprint Vaccines against human papilloma viruses
    Taff Jones
    GSK Biologicals North America, Clinical Serology, 525 Cartier Boulevard West, Laval H7V 3S8, Quebec, Canada
    Curr Opin Investig Drugs 7:699-701. 2006
  14. ncbi request reprint Hepagene (PowderJect)
    Taff Jones
    Intellivax International Inc, Ville St Laurent, Quebec, Canada
    Curr Opin Investig Drugs 3:987-91. 2002
    ..In December 1999, Lehman Brothers predicted that the product had a 50% chance of reaching the treatment (rather than prevention) market, with potential peak sales of US $600 million [352078]...
  15. ncbi request reprint Varivax (Merck & Co)
    Taff Jones
    Intellivax International Inc, Ville St Laurent, Quebec, Canada
    Curr Opin Investig Drugs 3:54-7. 2002
    ..Varivax II prevents the transmission of chickenpox with exactly the same safety and efficacy profile as Varivax; however, the new Varivax II has the advantage of being refrigerator-stable [371871]...
  16. ncbi request reprint StaphVAX (Nabi)
    Taff Jones
    Intellivax International Inc, Ville St Laurent, Quebec, Canada
    Curr Opin Investig Drugs 3:48-50. 2002
    ..At this time, Nabi was making plans for this second phase III trial, despite plans to appeal the FDA's decision [397729]...
  17. ncbi request reprint Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
    Mary C Hu
    GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway, Bothell, WA 98011, USA
    Vaccine 25:6334-40. 2007
    ..Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice...
  18. ncbi request reprint Respiration consists of two acts: first inspiration, then expect(or)ation
    Taff Jones
    Curr Opin Investig Drugs 9:833-5. 2008
  19. ncbi request reprint Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults
    Joanne M Langley
    Division of Infectious Diseases, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada
    Vaccine 24:1601-8. 2006
    ..Further testing of this nasal influenza vaccine is warranted to determine its safety and immunogenicity in these populations and its efficacy in the prevention of clinical illness...
  20. ncbi request reprint Vaccines to remember: managing health in our twilight years
    Taff Jones
    Expert Rev Vaccines 3:497-500. 2004
  21. ncbi request reprint IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection
    Taff Jones
    MedImmune Inc, 297 N Bernardo Ave, Mountain View, CA 94043, USA
    Curr Opin Mol Ther 10:407-17. 2008
    ..Additional phase II trials were ongoing in these groups at the time of publication and phase III trials were planned for 2009...